Susan B. Dillon, Ph.D. has end-to-end responsibility for Immunology small and large molecule research, drug discovery, biomarkers, translational medicine, clinical development and life cycle management. She leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for patients with serious autoimmune, inflammatory and respiratory diseases.
Sue joined the Johnson & Johnson Family of Companies through the Centocor Research & Development (R&D) Discovery Research Group in 2001 and has held positions of increasing responsibility leading to her 2007 appointment as Senior Vice President, Research, and Head of Early Development, Biologics. Under her leadership, the Centocor R&D Discovery organization produced a strong pipeline of novel biologic new molecular entities (NMEs) and built world-class capabilities in protein drug discovery through a combination of internal efforts, acquisitions and partnerships.
An experienced leader in large and small molecule drug discovery, Sue has held senior positions at several pharmaceutical companies, including SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Kosan Biosciences (acquired by Bristol Myers Squibb).
Sue earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University in Philadelphia, Pennsylvania. She completed a National Institutes of Health (NIH)-sponsored postdoctoral fellowship in Immunology at Duke University in Durham, North Carolina, has published more than 50 scientific articles and is inventor on three issued patents. In 2007, Sue was awarded the Distinguished Alumni Award from Thomas Jefferson University, and in 2013 she was selected by FierceBiotech as one of the “Top Women in Biotech.”